Company intelligence / Profile preview

Exsulin

Burnsville, Minnesota, United Statesabvancetherapeutics.com ↗

Ownership: Private
Development stage: Other

Overview

Exsulin developed a peptide-based therapy (INGAP peptide) aimed at regenerating insulin-producing islets in patients with type 1 and type 2 diabetes. Phase II clinical trials showed statistically significant improvements in C-peptide levels and A1C reduction, suggesting restoration or preservation of endogenous insulin secretion. The company targeted both new-onset and established type 1 diabetes patients, with studies conducted at Mayo Clinic and McGill University. There have been no recent clinical updates since the early-to-mid 2010s.

Therapeutic areas: Endocrinology
Modalities: PeptidesProtein (peptide-based drug)
Industry: Biotech

Drug pipeline

1 asset

INGAP peptide

Partnerships

Mayo Clinic (clinical trial site)McGill University (clinical trial site)

Beyond the preview

Go deeper on Exsulin.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Exsulin.

Explore the full profile